What is the address of VIZIPHAR Biosciences?

The registered office of VIZIPHAR Biosciences is located at Populierenlaan 14, 2460 Kasterlee.

Is VIZIPHAR Biosciences still active?

Yes. According to the CBE (29 October 2026) VIZIPHAR Biosciences is active, legal situation “Normale toestand”, started on 16 January 2004.

Is VIZIPHAR Biosciences registered on Peppol?

Yes, VIZIPHAR Biosciences is registered on the Peppol network with ID 0208:0862727797.

What is the enterprise number of VIZIPHAR Biosciences?

The enterprise number of VIZIPHAR Biosciences is BE0862727797.

When was VIZIPHAR Biosciences founded?

VIZIPHAR Biosciences was founded on 16 January 2004.

Who are the directors of VIZIPHAR Biosciences?

According to the 2025 annual accounts, the directors of VIZIPHAR Biosciences are: Gustaaf Van Reet.

Is VIZIPHAR Biosciences a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 January 2004; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did VIZIPHAR Biosciences make in 2025?

VIZIPHAR Biosciences posted a profit after taxes of € 31,255 in financial year 2025.

What is the revenue of VIZIPHAR Biosciences?

As a small company, VIZIPHAR Biosciences is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 6,212.

VIZIPHAR Biosciences (Private Limited) - Kasterlee

Dossier VIZIPHAR Biosciences, printed on 29 October 2026 from databakkes.be/en/0862727797/viziphar-biosciences. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

VIZIPHAR Biosciences from Kasterlee, company number BE0862727797, closed financial year 2025 with a result of € 31,255 after tax. For that financial year VIZIPHAR Biosciences recorded a gross margin of € 6,212 and equity of € 737,214. Compared with financial year 2024, the result moved from € 194,608 to € 31,255. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.

What it is worth Growing

€ 737,214

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 31,255

▼ 84% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 25,045

▲ 55% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 362,214.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 85

▼ 99% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,443

▼ 86% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 137,448 Gross margin 2022: € 137,448 First fiscal year in the series	€ 140,068 Gross margin 2023: € 140,068 ▲ 2% vs 2022 (€ 137,448) Favourable step	€ 434,061 Gross margin 2024: € 434,061 ▲ 210% vs 2023 (€ 140,068) Favourable step	€ 6,212 Gross margin 2025: € 6,212 ▼ 99% vs 2024 (€ 434,061) Unfavourable step	▼ 99%
Profit after taxes	€ 3,922 Profit after taxes 2022: € 3,922 First fiscal year in the series	€ 771 Profit after taxes 2023: € 771 ▼ 80% vs 2022 (€ 3,922) Unfavourable step	€ 194,608 Profit after taxes 2024: € 194,608 ▲ € 193,837 vs 2023 (€ 771) Favourable step	€ 31,255 Profit after taxes 2025: € 31,255 ▼ 84% vs 2024 (€ 194,608) Unfavourable step	▼ 84%
Equity	€ 510,580 Equity 2022: € 510,580 First fiscal year in the series	€ 511,351 Equity 2023: € 511,351 Unchanged (€ 510,580) Favourable step	€ 705,959 Equity 2024: € 705,959 ▲ 38% vs 2023 (€ 511,351) Favourable step	€ 737,214 Equity 2025: € 737,214 ▲ 4% vs 2024 (€ 705,959) Favourable step	▲ 4%
Total debts	€ 626,797 Total debts 2022: € 626,797 First fiscal year in the series	€ 496,630 Total debts 2023: € 496,630 ▼ 21% vs 2022 (€ 626,797) Favourable step	€ 481,516 Total debts 2024: € 481,516 ▼ 3% vs 2023 (€ 496,630) Favourable step	€ 45,687 Total debts 2025: € 45,687 ▼ 91% vs 2024 (€ 481,516) Favourable step	▼ 91%
Cash	€ 64,217 Cash 2022: € 64,217 First fiscal year in the series	€ 53,164 Cash 2023: € 53,164 ▼ 17% vs 2022 (€ 64,217) Unfavourable step	€ 16,159 Cash 2024: € 16,159 ▼ 70% vs 2023 (€ 53,164) Unfavourable step	€ 25,045 Cash 2025: € 25,045 ▲ 55% vs 2024 (€ 16,159) Favourable step	▲ 55%
Land & buildings	€ 1,042,115 Land & buildings 2022: € 1,042,115 First fiscal year in the series	€ 946,514 Land & buildings 2023: € 946,514 ▼ 9% vs 2022 (€ 1,042,115) Unchanged	€ 0 Land & buildings 2024: € 0 ▼ 100% vs 2023 (€ 946,514) Unchanged	-
Retained profit	€ 135,580 Retained profit 2022: € 135,580 First fiscal year in the series	€ 136,351 Retained profit 2023: € 136,351 ▲ 1% vs 2022 (€ 135,580) Favourable step	€ 330,959 Retained profit 2024: € 330,959 ▲ 143% vs 2023 (€ 136,351) Favourable step	€ 362,214 Retained profit 2025: € 362,214 ▲ 9% vs 2024 (€ 330,959) Favourable step	▲ 9%
Bank debt	€ 123,957 Bank debt 2022: € 123,957 First fiscal year in the series	€ 54,150 Bank debt 2023: € 54,150 ▼ 56% vs 2022 (€ 123,957) Favourable step	€ 6,250 Bank debt 2024: € 6,250 ▼ 88% vs 2023 (€ 54,150) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 6,250) Favourable step	▼ 100%
Balance sheet total	€ 1,137,377 Balance sheet total 2022: € 1,137,377 First fiscal year in the series	€ 1,007,981 Balance sheet total 2023: € 1,007,981 ▼ 11% vs 2022 (€ 1,137,377) Unchanged	€ 1,187,475 Balance sheet total 2024: € 1,187,475 ▲ 18% vs 2023 (€ 1,007,981) Unchanged	€ 782,901 Balance sheet total 2025: € 782,901 ▼ 34% vs 2024 (€ 1,187,475) Unchanged	▼ 34%

Key figures of VIZIPHAR Biosciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VIZIPHAR Biosciences?

What happened at VIZIPHAR Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 19, 2026 New annual accounts for financial year 2025: profit of € 31,255 (▼ 84% vs 2024). Source: NBB ↗
2023 Gustaaf Van Reet became a director. NBB
Jan 16, 2004 New establishment in Kasterlee. KBO
Jan 16, 2004 Start of the company according to the CBE. KBO

In short

From € 3,922 profit in 2022 to € 31,255 profit in 2025.

Paid € 103,784 in corporate taxes since 2022.

Best year ever: 2024, with € 194,608 profit.

Original PDFs at the National Bank ↗

Management

Gustaaf Van Reet

VIZIPHAR Biosciences

VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY

OCTIMET Oncology

DeuterOncology

Behind VIZIPHAR Biosciences is Gustaaf Van Reet. Gustaaf Van Reet is also behind VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, OCTIMET Oncology and DeuterOncology.

Directors

According to the 2025 annual accounts

Gustaaf Van Reet

Director

Also active at: VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, OCTIMET Oncology, DeuterOncology

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Populierenlaan 14

2460 Kasterlee

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0862.727.797
VAT number: BE 0862.727.797
Registered office: Populierenlaan 14, 2460 Kasterlee
Names & denominations: VIZIPHAR Biosciences
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 16 January 2004
Peppol: Active · Active since 19 Aug 2025

View on CBE Public ↗ Annual accounts (NBB) ↗